Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methodsMarieke Henstra, Didi Rhebergen, Rob Kok et al.|Frontiers in Psychiatry|2022Cited by 6